• Revenue Cycle Management
  • COVID-19
  • Reimbursement
  • Diabetes Awareness Month
  • Risk Management
  • Patient Retention
  • Staffing
  • Medical Economics® 100th Anniversary
  • Coding and documentation
  • Business of Endocrinology
  • Telehealth
  • Physicians Financial News
  • Cybersecurity
  • Cardiovascular Clinical Consult
  • Locum Tenens, brought to you by LocumLife®
  • Weight Management
  • Business of Women's Health
  • Practice Efficiency
  • Finance and Wealth
  • EHRs
  • Remote Patient Monitoring
  • Sponsored Webinars
  • Medical Technology
  • Billing and collections
  • Acute Pain Management
  • Exclusive Content
  • Value-based Care
  • Business of Pediatrics
  • Concierge Medicine 2.0 by Castle Connolly Private Health Partners
  • Practice Growth
  • Concierge Medicine
  • Business of Cardiology
  • Implementing the Topcon Ocular Telehealth Platform
  • Malpractice
  • Influenza
  • Sexual Health
  • Chronic Conditions
  • Technology
  • Legal and Policy
  • Money
  • Opinion
  • Vaccines
  • Practice Management
  • Patient Relations
  • Careers

Friday 5 from Rheumatology Network – May 14


The Friday 5 from Rheumatology Network is a list composed by the Rheumatology Network editorial staff aimed at highlighting relevant coverage of the latest news in rheumatology.

This week, the Friday 5 from Rheumatology Network highlights the latest rheumatic disease treatments and trends, why patients are avoiding healthcare during the COVID-19 pandemic, and how oral microbiome can be an indicator of rheumatoid arthritis.

1. Oral Microbiome Linked to Onset of Rheumatoid Arthritis

Both patients with early rheumatoid arthritis (ERA) and those at-risk for developing rheumatoid arthritis (RA) had a significantly different oral microbiome when compared with a control group. Most notably, the pro-inflammatory discriminative zero-radius operational taxonomic units (zOTUs), Prevotella and Veillonella, were much more prevalent in these groups than in patients with no history of autoimmune conditions.

2. Apremilast Monotherapy Proves Effective Treatment for Psoriatic Arthritis

Patients with oligoarticular psoriatic arthritis (PsA) receiving apremilast monotherapy fared better than those who initiated methotrexate (MTX) therapy or biologic disease-modifying antirheumatic drug (bDMARD) initiators.

3. Biologics May Increase Risk of Infection in Patients With Rheumatoid Arthritis

Patients receiving csDMARDs had a significant reduction (40%) in non-serious infection (NSI) risk when compared with biologics.

4. Patients With Rheumatic Diseases Are More Likely to Avoid Healthcare During COVID-19 Pandemic

Poorer results were associated with lower socioeconomic status (SES) and not being able to access telehealth, which emphasizes the need for access to healthcare and attention to vulnerable populations, such as those with rheumatic diseases, during the pandemic.

5. Gender, Not Alcohol Consumption, is Linked to Remission in Patients With Inflammatory Arthritis

While men with inflammatory arthritis drink significantly more alcohol and have less severe disease activity, alcohol is not linked to disease remission.

Related Videos
Victor J. Dzau, MD, gives expert advice
Victor J. Dzau, MD, gives expert advice
Monica Verduzco-Gutierrez, MD, FAAPMR, gives expert advice
Monica Verduzco-Gutierrez, MD, FAAPMR, gives expert advice
Monica Verduzco-Gutierrez, MD, FAAPMR, gives expert advice
Monica Verduzco-Gutierrez, MD, FAAPMR, gives expert advice